Skip to main content
OpenTrials
Completed

NCT Number: NCT01690312

Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy

The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nutrasource Diagnostics Inc.

Guelph, Ontario, N1G 0B4, Canada

About this study

This study involves fasted and post-prandial components.

Fasted Study:

Participants will provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo] in Treatment Period I. Participants will again provide fasting blood samples pre-and post-intervention [4-week administration of supplement or placebo, opposite to Treatment Period I] during Treatment Period II.

There will be a 4-week washout period during the two Treatment Periods.

Post-prandial study:

Participants will also complete a post-prandial study pre-and post-intervention during each Treatment Period.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be an adult between the ages of 18 and 70;
  • Be a male or a post-menopausal female who has gone a minimum of one year since their last menses;
  • Be taking Statin medication at a stable dose for a minimum of four weeks prior to study commencement [and whom have reached a target LDL level];
  • Have elevated fasting triglyceride levels [greater than 1.5 mmol/L but less than 5.7 mmol/L];
  • Have fasting blood glucose levels below the study cut-off [less than 7.0 mmol/L];
  • Have a Body Mass Index (BMI) less than 35.0
  • Be taking natural health products BUT agree to cease consumption during the study period and a 4-week pre-study washout prior to study commencement. Study participants will be allowed to consume a daily multivitamin if they have been doing so at a stable dose for a minimum of three months prior to study commencement.

Exclusion criteria

  • Be younger than 18 years of age or older than 70 years of age;
  • Be an adult pre- or peri-menopausal female;
  • Not have taken Statin medication at a stable dose for a minimum of 4 weeks prior to study commencement;
  • Have fasting triglyceride levels outside of study limits[ie/ less than 1.5 mmol/L or greater than 5.7 mmol/L];
  • Have elevated fasting blood glucose levels [greater or equal to 7.0 mmol/L];
  • Have high blood pressure [greater than 140/100]
  • Have a Body Mass Index (BMI) equal to or greater than 35.0
  • Have a pre-existing cardiovascular disease or illness, including angina, myocardial infarction, stroke, intermittent claudication or transient ischemic attack;
  • Have a known allergy to fish and/or fish oil, olive oil, soy or Vitamin E;
  • Be taking natural health products but are unwilling to cease consumption during the study period and a 4-week pre-study washout prior to study commencement;
  • Consume more than two (2) fish meals on a weekly basis
  • Consume excessive amounts of alcohol on a weekly basis [more than 10 alcoholic drinks per week];
  • Anticipate or have planned surgery during the course of the study.

Treatment and study plan

Fish Oil

Dietary Supplement

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].

Placebo

Dietary Supplement

On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.

Primary outcomes

  1. Triglyceride [TG]

    Time frame: 0 and 4 weeks

    Fasted and postprandial samples will be drawn (hourly up to 6 hours).

Secondary outcomes

  1. Glucose

    Time frame: 0 and 4 weeks

    Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).

  2. Insulin

    Time frame: 0 and 4 weeks

    Fasted and postprandial samples will be drawn (every 30 minutes up to 2 hours).

  3. Total cholesterol [TC]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  4. High-density lipoprotein [HDL]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  5. Low-density lipoprotein [LDL]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  6. Very low-density lipoprotein [VLDL]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  7. Lipoprotein A

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  8. Intermediate-density lipoprotein [IDL]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  9. Remnant Lipoproteins

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  10. High-sensitivity C-Reactive Protein [hs-CRP]

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  11. Homocysteine

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  12. Essential Fatty Acid Profile

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  13. Apolipoprotein B

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

  14. Apolipoprotein A-1

    Time frame: 0 and 4 weeks

    A fasted blood sample will be taken.

Sponsors and collaborators

Lead sponsor

Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

Network

Collaborators

  • Biodroga Inc.
  • University of Guelph

Registry information

Official study title

Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Sep 21, 2012
Registry last updated
Feb 7, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.